| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17530059.2013.846321 |
| P698 | PubMed publication ID | 24161073 |
| P2093 | author name string | Jason T Huse | |
| Kenneth D Aldape | |||
| P2860 | cites work | Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres | Q24292850 |
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
| Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme | Q24555728 | ||
| Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma | Q24612429 | ||
| Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas | Q24629777 | ||
| An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
| IDH1 and IDH2 mutations in gliomas | Q24648948 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| CpG island methylator phenotype in colorectal cancer | Q24672170 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain | Q27865182 | ||
| ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells | Q28114801 | ||
| Mutations in CIC and FUBP1 contribute to human oligodendroglioma | Q28244895 | ||
| Distinct factors control histone variant H3.3 localization at specific genomic regions | Q28275277 | ||
| Histological assessment of PAXgene tissue fixation and stabilization reagents | Q28742648 | ||
| Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue | Q28742831 | ||
| IDH mutation impairs histone demethylation and results in a block to cell differentiation | Q29305058 | ||
| Direct multiplexed measurement of gene expression with color-coded probe pairs | Q29614417 | ||
| Highly recurrent TERT promoter mutations in human melanoma | Q29614798 | ||
| TERT promoter mutations in familial and sporadic melanoma | Q29614920 | ||
| Malignant gliomas in adults | Q29615708 | ||
| Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Q29616862 | ||
| IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype | Q29617457 | ||
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
| High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing | Q30514084 | ||
| Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations | Q30885944 | ||
| Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression | Q30951772 | ||
| DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues | Q31068101 | ||
| Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review | Q33184436 | ||
| Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial | Q33223508 | ||
| Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival | Q33621327 | ||
| Proteomic analysis of PAXgene-fixed tissues | Q33682643 | ||
| The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas | Q33691337 | ||
| Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship | Q33719798 | ||
| EGFRvIII-targeted vaccination therapy of malignant glioma | Q33758459 | ||
| Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease | Q33990951 | ||
| Genome-wide expression assay comparison across frozen and fixed postmortem brain tissue samples | Q34015378 | ||
| A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival | Q34108339 | ||
| Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas | Q34150635 | ||
| PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas | Q34164924 | ||
| IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. | Q34194743 | ||
| Altered telomeres in tumors with ATRX and DAXX mutations | Q34196696 | ||
| Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma | Q34308674 | ||
| Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway | Q34350929 | ||
| Molecular classification of low-grade diffuse gliomas | Q34358250 | ||
| Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas | Q34428834 | ||
| Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays | Q35103313 | ||
| Proteomics of gliomas: initial biomarker discovery and evolution of technology | Q35170365 | ||
| Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma | Q35532490 | ||
| Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma | Q35633805 | ||
| Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response | Q35779256 | ||
| MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity | Q36010084 | ||
| Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas | Q36236484 | ||
| TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal | Q36762656 | ||
| GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. | Q36798779 | ||
| A portrait of tissue phosphoprotein stability in the clinical tissue procurement process | Q36919993 | ||
| Structural alterations of the epidermal growth factor receptor gene in human gliomas | Q36930689 | ||
| Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. | Q37065952 | ||
| Genetically engineered mouse models of brain cancer and the promise of preclinical testing | Q37348716 | ||
| Next-generation sequencing in the clinic: are we ready? | Q37478694 | ||
| Polycomb group proteins: navigators of lineage pathways led astray in cancer | Q37620148 | ||
| Understanding the language of Lys36 methylation at histone H3. | Q37672319 | ||
| Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade | Q37815544 | ||
| Genetic modeling of gliomas in mice: new tools to tackle old problems | Q37838362 | ||
| Signal transduction inhibitors and antiangiogenic therapies for malignant glioma | Q37847104 | ||
| Molecular subclassification of diffuse gliomas: seeing order in the chaos | Q37858944 | ||
| Current clinical development of PI3K pathway inhibitors in glioblastoma | Q38012438 | ||
| Statistical challenges associated with detecting copy number variations with next-generation sequencing. | Q38040034 | ||
| Whole genome SNP arrays using DNA derived from formalin-fixed, paraffin-embedded ovarian tumor tissue | Q38441304 | ||
| Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers | Q40008535 | ||
| Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers | Q40923195 | ||
| Platelet-derived growth factor in human glioma | Q40961503 | ||
| Loss of ATRX leads to chromosome cohesion and congression defects | Q41825660 | ||
| MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma | Q41962843 | ||
| Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma | Q42013793 | ||
| A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs | Q42218583 | ||
| Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis | Q42738436 | ||
| Different angiogenic phenotypes in primary and secondary glioblastomas | Q42803768 | ||
| Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations | Q44269667 | ||
| Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. | Q45918451 | ||
| Distinct transcription profiles of primary and secondary glioblastoma subgroups. | Q46259525 | ||
| MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients | Q46619783 | ||
| Gene expression profiling identifies molecular subtypes of gliomas | Q47719947 | ||
| Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype | Q48144051 | ||
| Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. | Q48221611 | ||
| Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets | Q48315065 | ||
| Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma | Q48329991 | ||
| Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas | Q48374829 | ||
| Platelet-derived growth factor and its receptor expression in human oligodendrogliomas | Q48524373 | ||
| IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival | Q49109048 | ||
| Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. | Q52544855 | ||
| Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. | Q53201476 | ||
| Universal, robust, highly quantitative SNP allele frequency measurement in DNA pools. | Q53668847 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 573-587 | |
| P577 | publication date | 2013-10-28 | |
| P1433 | published in | Expert Opinion on Medical Diagnostics | Q5421210 |
| P1476 | title | The molecular landscape of diffuse glioma and prospects for biomarker development | |
| P478 | volume | 7 |
| Q54356942 | ACVR1 mutations and the genomic landscape of pediatric diffuse glioma. |
| Q38892824 | Clinical ramifications of "genomic staging" of low-grade gliomas. |
| Q91834962 | Novel insights into the epigenetics of diffuse glioma |
| Q42396770 | TERT promoter mutation designates biologically aggressive primary glioblastoma |
| Q38349169 | The evolving molecular genetics of low-grade glioma |
| Q34982039 | Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. |
| Q36557234 | miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas |
Search more.